Walleye Trading’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.53M | Buy |
64,700
+13,200
| +26% | +$696K | ﹤0.01% | 1507 |
|
|
2026
Q1 | $2.45M | Sell |
51,500
-9,700
| -16% | -$512K | ﹤0.01% | 1582 |
|
|
2025
Q4 | $3.21M | Sell |
61,200
-13,300
| -18% | -$797K | ﹤0.01% | 1585 |
|
|
2025
Q3 | $4.83M | Sell |
74,500
-7,500
| -9% | -$431K | 0.01% | 1270 |
|
|
2025
Q2 | $3.99M | Buy |
82,000
+1,300
| +2% | +$50.3K | 0.01% | 1331 |
|
|
2025
Q1 | $2.75M | Buy |
80,700
+37,500
| +87% | +$1.59M | 0.01% | 1431 |
|
|
2024
Q4 | $1.7M | Buy |
43,200
+25,700
| +147% | +$1.21M | ﹤0.01% | 1789 |
|
|
2024
Q3 | $822K | Buy |
17,500
+7,700
| +79% | +$391K | ﹤0.01% | 2223 |
|
|
2024
Q2 | $529K | Sell |
9,800
-27,600
| -74% | -$1.6M | ﹤0.01% | 2467 |
|
|
2024
Q1 | $2.55M | Sell |
37,400
-75,900
| -67% | -$5.43M | 0.01% | 1582 |
|
|
2023
Q4 | $7.09M | Buy |
113,300
+64,400
| +132% | +$3.56M | 0.02% | 1006 |
|
|
2023
Q3 | $2.22M | Buy |
48,900
+5,900
| +14% | +$305K | 0.01% | 1709 |
|
|
2023
Q2 | $2.41M | Sell |
43,000
-198,900
| -82% | -$11.3M | 0.01% | 1511 |
|
|
2023
Q1 | $10.9M | Buy |
241,900
+129,100
| +114% | +$6.27M | 0.02% | 597 |
|
|
2022
Q4 | $4.59M | Sell |
112,800
-51,300
| -31% | -$2.72M | 0.01% | 1130 |
|
|
2022
Q3 | $10.7M | Sell |
164,100
-500
| -0.3% | -$36.2K | 0.03% | 591 |
|
|
2022
Q2 | $10M | Buy |
164,600
+67,800
| +70% | +$3.99M | 0.03% | 610 |
|
|
2022
Q1 | $6.08M | Buy |
96,800
+78,300
| +423% | +$4.92M | 0.02% | 887 |
|
|
2021
Q4 | $1.4M | Sell |
18,500
-600
| -3% | -$52.4K | ﹤0.01% | 1940 |
|
|
2021
Q3 | $2.14M | Buy |
19,100
+2,300
| +14% | +$289K | 0.01% | 1563 |
|
|
2021
Q2 | $2.72M | Buy |
16,800
+6,900
| +70% | +$839K | 0.01% | 1239 |
|
|
2021
Q1 | $1.21M | Buy |
9,900
+3,700
| +60% | +$559K | 0.01% | 1743 |
|
|
2020
Q4 | $949K | Buy |
6,200
+5,900
| +1,967% | +$697K | ﹤0.01% | 2012 |
|
|
2020
Q3 | $25K | Sell |
300
-1,000
| -77% | -$88.7K | ﹤0.01% | 3801 |
|
|
2020
Q2 | $96K | Sell |
1,300
-5,000
| -79% | -$292K | ﹤0.01% | 3535 |
|
|
2020
Q1 | $267K | Sell |
6,300
-48,300
| -88% | -$2.49M | ﹤0.01% | 2375 |
|
|
2019
Q4 | $3.33M | Buy |
54,600
+10,800
| +25% | +$590K | 0.02% | 839 |
|
|
2019
Q3 | $1.79M | Buy |
43,800
+43,300
| +8,660% | +$2.07M | 0.02% | 1139 |
|
|
2019
Q2 | $24K | Sell |
500
-9,300
| -95% | -$372K | ﹤0.01% | 3706 |
|
|
2019
Q1 | $350K | Sell |
9,800
-15,700
| -62% | -$543K | ﹤0.01% | 2566 |
|
|
2018
Q4 | $729K | Buy |
25,500
+24,900
| +4,150% | +$866K | 0.01% | 2076 |
|
|
2018
Q3 | $27K | Buy |
+600
| New | +$31.4K | ﹤0.01% | 4757 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Walleye Trading's CRSP Position: Q2 2026 in Review
Walleye Trading increased its CRISPR Therapeutics (CRSP) stake by 23% in Q2 2026, buying an estimated $185K and bringing the position to 18,595 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2288.
Walleye Trading first reported a position in CRSP in Q4 2018 and has held it in 13 quarters since. The position peaked at $1.7M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Walleye Trading held 18,595 shares of CRISPR Therapeutics worth $1.01M as of Q2 2026.
- Walleye Trading bought 3,509 CRISPR Therapeutics shares in Q2 2026, an estimated $185K.
- CRISPR Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2288 holding.
- Walleye Trading first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 13 quarters since.
- Walleye Trading's CRISPR Therapeutics position peaked at $1.7M in Q2 2021.
- 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.